Medibank Partners with Emyria to Fund Innovative PTSD Treatment Program in Australian Healthcare First
Key Insights
Medibank (search), Australia's largest private health insurer, has entered a multi-year partnership with Emyria to fund the Empax (search) PTSD (search) care program, marking the first time a major private health insurer has funded an ethics-approved, psychiatrist-led trauma therapy program.
Eligible Medibank (search) members can now access the comprehensive trauma care program with no out-of-pocket costs at Perth Clinic (search), with treatment typically valued between AUD $20,000 and AUD $30,000.
The Empax (search) model integrates psychiatrist-supervised therapy, specialist care coordination, and continuous real-world data collection, addressing the urgent need for innovative mental health treatments as PTSD (search) affects approximately one in 11 Australians.
Emyria Limited (search) has announced a landmark partnership with Medibank (search), Australia's largest private health insurer, to fund its innovative Empax (search) PTSD (search) care program. This multi-year agreement represents the first time a major private health insurer has funded an ethics-approved, psychiatrist-led trauma therapy program of this kind, setting a new global precedent in mental health care.
Under the partnership, eligible Medibank (search) members can now access Emyria's comprehensive psychological trauma care with no out-of-pocket costs once admitted to the Perth Clinic (search), a licensed hospital site. The program is now live and accepting eligible Medibank members following clinical screening.
Comprehensive Treatment Model
The Empax (search) model integrates psychiatrist-supervised therapy, specialist care coordination, and continuous real-world data collection to support lasting outcomes. While treatment is personalized for each participant, the comprehensive care program typically represents a value of between AUD $20,000 and AUD $30,000.
Key components of the program include psychiatrist-led, ethics-endorsed care protocols delivered by trained clinicians, rigorous patient selection and screening planning, fit-for-purpose treatment environments, strong clinical governance frameworks, integrated data capture and analysis to support continuous improvement, and durable real-world outcomes.
Addressing Critical Mental Health Needs
The partnership addresses a significant healthcare challenge, as PTSD (search) affects approximately one in 11 Australians, with a higher prevalence among women and first responders. Emyria Executive Chairman Greg Hutchinson emphasized the urgent need for innovative approaches to mental health treatment.
"Whilst we've seen great advances in many areas of medicine over the past 20 years, mental health incidence and prevalence have increased to unacceptable levels," Hutchinson commented. "It's clear that mental health requires not just more resources, but a multi-faceted, multi-stakeholder and more innovative approach."
Clinical Validation and Evaluation
Independent mental health expert Professor Paul Fitzgerald from the Australian National University will evaluate outcomes from Medibank (search)'s program. The assessments will cover clinical effectiveness and health economics, helping build the case for broader reimbursement and systemic adoption.
Dr Michael Winlo, Emyria's Chief Scientific Officer and Executive Director, highlighted the significance of the partnership: "This milestone shows how private health systems can help unlock access to promising, evidence-informed treatments and is a testament to our clinical, research and operational teams who continue to set a new standard for mental health care, world-wide."
Future Expansion Plans
Emyria is actively progressing a national expansion strategy that will see it open new Empax (search) centres across key locations in the eastern states and forge partnerships with additional private hospitals and health insurance funds. The company also hopes to deploy its scalable care framework to address treatment-resistant depression (search) and expand the use of its real-world data platform to support health economics validation, regulatory engagement and additional funding opportunities.
Winlo expressed optimism about the broader implications: "This agreement demonstrates that the private health system can play a key role in unlocking access to promising, evidence-informed therapies. We believe this is just the beginning of a wider shift in how mental health care is supported in Australia and we are proud to be at the forefront."